Corrigendum to “167 - An audit of the management of mesothelioma in Southern England” Lung Cancer 139 (Suppl. 1) (January 2020) S72–S73

The authors regret that one author ’s name was written incorrectly, being S. Prince instead of S. Austin. It has been corrected in this corrigendum.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Tags: Corrigendum Source Type: research

Related Links:

This study aims to evaluate micronuclei (MN) frequency as a biomarker of genome instability in peripheral blood lymphocytes of PM and lung cancer (LC) patients when compared with healthy controls (HCs) and patients with nonneoplastic respiratory diseases (RDs). Lymphocyte cytokinesis-block MN assay was carried out on 317 subjects. Mutagen sensitivity, measured by quantifying MN frequency after an in vitro challenge with ionizing radiation, was evaluated in 252 subjects. A significant increase in MN frequency was observed in cancer patients compared to HCs, with a mean ratio (MR) of 1.35 and 1.36 at baseline and 1.43 and 1....
Source: Journal of Environmental Pathology, Toxicology and Oncology - Category: Environmental Health Tags: J Environ Pathol Toxicol Oncol Source Type: research
Doctors, scientists and occupational health experts from across the country are openly criticizing the U.S. Environmental Protection Agency’s recent asbestos draft risk evaluation. At a virtual press conference arranged by the Asbestos Disease Awareness Organization last week, speakers labeled the asbestos evaluation inadequate and in need of serious revision. The year-long evaluation was required as part of the Frank R. Lautenberg Chemical Safety for the 21st Century Act, which was passed in 2016. It amended the original Toxic Substances Control Act, the country’s primary chemicals management law. “I am...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
We examined 329 patients from February 2002 to July 2013. There were 131 MPM cases with ADA levels of 32.29 IU/L; 117 LC cases with ADA levels of 21.12 IU/L; 54 benign disease cases with ADA levels of 20.98 IU/L. A significant difference existed in pleural effusion ADA levels between MPM and benign disease patients. Pleural effusion ADA levels were significantly higher in MPM patients. PMID: 32468861 [PubMed - as supplied by publisher]
Source: Cancer Investigation - Category: Cancer & Oncology Tags: Cancer Invest Source Type: research
Malignant pleural mesothelioma (MPM) is a highly aggressive cancer of the visceral or parietal pleura, with greater than 90% of cases occurring in the setting of asbestos exposure. It is a relatively rare cancer, with an incidence of approximately 10 per 1 million person-years in the United States. It has a long latency period, up to 20 years after asbestos exposure, and the median age of diagnosis is 75 years old. [1,2]
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Identifying rare subsets of thoracic tumors with gene fusions has redefined therapeutic paradigms. Gene rearrangements involving neurotrophic tropomyosin receptor kinase, (NTRK)1, NTRK2, NTRK3, c-ROS oncogene 1 (ROS1) and the anaplastic lymphoma kinase gene (ALK), result in oncogenic fusion proteins that are detectable using immunohistochemistry screening with variable sensitivity and specificity [1 –3].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
This article is protected by copyright. All rights reserved. PMID: 32437065 [PubMed - as supplied by publisher]
Source: Cell Biology International - Category: Cytology Authors: Tags: Cell Biol Int Source Type: research
Malignant pleural mesothelioma (MPM) is a rare and aggressive malignant tumor primarily affecting the pleura with approximately 80 % of cases resulting from occupational or environmental asbestos exposure [1 –4]. The MPM incidence is suspected to increase in the future in many countries in which asbestos either has not yet been banned or is still largely used. The prognosis of MPM is very poor, with a median survival time between 12 and 18 months and a 5-year survival rate of
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Johnson &Johnson announced Tuesday that it will stop selling its iconic, talc-based baby powder, the target of thousands of lawsuits claiming that its talc was contaminated with asbestos, which led to cancers such as mesothelioma and ovarian cancer. The company said the stoppage is only in the United States and Canada, citing a decline in consumer demand and “misinformation” about the safety of the product. “Demand for talc-based Johnson’s Baby Powder in North America has been declining due in large part to changes in consumer habits and fueled by misinformation around the safety of the product ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Pemetrexed is widely used as an anti-folate cytostatic agent for the treatment of non-small cell lung cancer (NSCLC), mesothelioma and thymoma. [1 –5] Dependent on treatment indication, therapy generally exists of four cycles of induction therapy with pemetrexed and a platinum-agent, which can be combined with the recently approved programmed death-ligand 1 (PD-L1) targeting monoclonal antibody pembrolizumab [6]. Pemetrexed - and, if applica ble, pembrolizumab - can be continued as maintenance treatment following the induction period [3,6].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
The Scientific Analytical Institute in Greensboro, North Carolina, recently uncovered asbestos-contaminated talc in two new eyeshadow makeup products sold online on sites like Amazon and eBay. Its findings were the latest example in a growing list of talc-based cosmetic products found to contain toxic asbestos. Scientific Analytical Institute found asbestos fibers in 40% of the shades tested in Jmkcoz 120 Colors Eyeshadow Palette. It found traces of asbestos in 20% of the shades tested in the Beauty Glazed Gorgeous Me Eye Shadow Tray Palette. The results were released by the Environmental Working Group in Washington, D.C.,...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
More News: Asbestosis | Cancer | Cancer & Oncology | Lung Cancer | Mesothelioma